|
| Nicotinic acid (5-bromo-2-hydroxy-benzylidene)-hydrazide |
|
Salmonella
Shigella |
TTSS (SPI-1 encode); TTSS (SPI-2 encode)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vitro) |
Negrea A, et al. 2007. Antimicrob Agents Chemother
Veenendaal AK, et al. 2009. J Bacteriol |
|
| N-[2-[4-(benzimidazol-1-yl)anilino]-2-oxoethyl]-3-chloro-1-benzothiophene-2-carboxamide |
|
Salmonella
Yersinia |
TTSS (SPI-1 encode)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vivo) |
Boonyom R, et al. 2022. J Genet Eng Biotechnol
Swietnicki W, et al. 2011. PLoS One |
|
| (E)-N-(6-methylsulfonyl-1,3-benzothiazol-2-yl)-3-[3-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]prop-2-enamide |
|
Shigella |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Case HB, et al. 2018. Biochemistry |
|
| 1'-butyl-4'-(nitromethyl)-1',4'-dihydro-2,3'-biquinoline |
|
Shigella |
VirF |
Preclinical (in vitro) |
Koppolu V, et al. 2013. Infect Immun |
|
| 4-Methoxy-beta-nitrostyrene |
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen |
|
| 1-Phenyl-3-(1,2,3-thiadiazol-5-yl)urea |
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen; Emanuele AA, et al. 2014. J Antibiot (Tokyo); Emanuele AA, et al. 2015. PLoS One |
|
| 4-Aminoquinaldine |
|
Shigella |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Dey S, et al. 2017. ChemMedChem |
|
| 3,5-di(3-pyridylmethyl)-1,3,5-thiadiazinane-2-thione |
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen |
|
| 2-phenyl-2,3-dihydrophthalazine-1,4-dione |
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen |
|
| 4-(2-(Pyrrolidin-1-yl)ethyl)aniline |
|
Shigella |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Dey S, et al. 2017. ChemMedChem |
|
| | | |
